The GCC & UAE diabetes devices market, valued at USD 3.35 billion in 2025, is projected to reach USD 6.84 billion by 2035, growing at a CAGR of 7.40%, driven by rising diabetes prevalence, technological advancements, and increasing healthcare investments.

GCC and UAE Diabetes Devices Market Statical Scope

The market in the GCC and the UAE is mainly influenced by high rates of diabetes, rapid adoption of advanced technologies such as Artificial Intelligence -driven Continuous Glucose Monitoring (CGM) systems, and substantial government funding for healthcare infrastructure.

This market is vital due to the region's notably high diabetes rates, which require advanced, technology-based management tools. The growing need for CGM systems, smart insulin pumps, and AI solutions is shifting care from a reactive approach to proactive monitoring. With high income levels and strong healthcare systems, there are significant opportunities for international companies to introduce premium healthcare technologies.

GCC and UAE Diabetes Devices Market Share, By Services, 2025 (%)

• Devices and Wearables - Devices and wearables dominate the market segment, fueled by the increasing use of continuous glucose monitoring systems, insulin delivery devices, and digital health tracking tools, capturing a 30% share that indicates a strong demand for real-time diabetes management solutions.
• Pharma, Drugs and Supplies - Pharmaceuticals, drugs, and supplies represent a significant share, driven by the ongoing need for insulin, medications, and testing supplies, holding a 25% share across the region.
• Technology Platforms and Products - Technology platforms and products are growing due to the rise of digital health integration, data analytics, and remote patient monitoring solutions, accounting for 12% of the market.

GCC and UAE Diabetes Devices Market Share, By Distribution Channel, 2025 (%)

• Hospital Pharmacies - Hospital pharmacies lead the market, with a 55% share, fueled by a high patient volume, access to specialized medications, and comprehensive treatment services.
• Retail Pharmacies - Retail pharmacies maintain a strong presence, bolstered by their accessibility, convenience, and widespread locations in both urban and rural settings, with a 20% share.
• Diabetes Clinics/Centers - Diabetes clinics and centers represent 11% of the market, driven by specialized care and targeted diabetes management programs.

GCC and UAE Diabetes Devices Market Share, By End-use, 2025 (%)

• Hospitals - Hospitals are at the forefront of the market, supported by advanced treatment facilities, the presence of specialized healthcare professionals, and a large patient base, with a 43% share.
• Homecare - Homecare services capture a significant market share, driven by the growing preference for managing diabetes at home, the use of wearable technology, and remote monitoring options, holding a 37% share.
• Diagnostic Centers - Diagnostic centers hold 20% of the market, driven by the need for regular testing, early diagnosis, and monitoring of diabetes-related issues.

Top Companies in the GCC and UAE Diabetes Devices Market

• Medtronic
• Abbot Laboratories
• Ascensia Diabetes Care Holdings
• Dexcom
• F. Hoffmann- La Roche AG,
• Sanofi
• Novo Nordisk A/S
• Insulet Corporation
• Ypsomed AG
• Eli Lily
• Astra Zeneca

Segments Covered in the Report

By Services

• Devices and Wearables
• Pharma, Drugs and Supplies
• Technology Platforms and products
• Genomics and Multi omics
• Diabetes Prevention
• Diabetes Researches
• Primary Care

By Distribution Channel

• Hospital pharmacies
• Retail Pharmacies
• Diabetes Clinics/ Centers
• Online Pharmacies
• Others

By End-use

• Hospitals
• Homecare
• Diagnostic centers